Arthneeti
Dividend / buyback / bonusNotableFiled on BSE ·

Zydus Lifesciences Q4 FY26 adjusted net profit up 14.6%; buyback up to Rs. 11,000 mn

Zydus Lifesciences · Pharmaceuticals & Biotechnology

Arthneeti Research DeskPublished 1 min read
₹1,100 CrDividend / buyback / bonus

Key highlights

  • Q4 FY26 revenue from operations Rs. 75,870 mn, up 16.2% YoY; EBITDA Rs. 25,544 mn, up 20.2%; adjusted net profit Rs. 15,929 mn, up 14.6%
  • FY26 revenue from operations Rs. 2,71,484 mn, up 16.8%; EBITDA Rs. 84,751 mn, up 20.1%; adjusted net profit Rs. 54,564 mn, up 15.0%
  • Board recommended a dividend of 100% for FY2025-26 and approved a buyback of up to Rs. 11,000 mn at Rs. 1,150 per share

Why it's rated notable: amount is ₹500 crore or more

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Zydus Lifesciences

Other dividend / buyback / bonus filings this fortnight

All dividend / buyback / bonus filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.